Inhibikase Therapeutics, Inc.
IKT
$1.66
-$0.01-0.60%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -28.63% | -6.74% | -20.32% | 27.51% | -12.74% |
| Total Depreciation and Amortization | -- | -100.00% | -2.07% | 90.55% | 92.42% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -9.11% | 38.93% | -10.09% | -53.24% | 4.12% |
| Change in Net Operating Assets | -112.32% | 119.05% | -560.15% | -64.85% | 217.72% |
| Cash from Operations | -60.45% | 29.05% | -90.03% | -35.84% | 23.24% |
| Capital Expenditure | -- | -- | -- | 100.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -81,362.15% | 99.66% | -392.03% | -53.28% | 154.35% |
| Cash from Investing | -81,362.15% | 99.66% | -392.03% | -53.25% | 154.32% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -97.32% | 43,016.90% | 688.99% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 200.00% | -- | -- | -- |
| Cash from Financing | -97.33% | 81,058.46% | -521.70% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -188.80% | 355.75% | -1,017.70% | -74.62% | -69.50% |